Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.140
+0.230 (12.04%)
At close: Mar 9, 2026, 4:00 PM EDT
2.140
0.00 (0.00%)
After-hours: Mar 9, 2026, 6:20 PM EDT
Ovid Therapeutics Employees
Ovid Therapeutics had 23 employees as of December 31, 2024. The number of employees decreased by 17 or -42.50% compared to the previous year.
Employees
23
Change (1Y)
-17
Growth (1Y)
-42.50%
Revenue / Employee
$287,391
Profits / Employee
-$1,559,652
Market Cap
278.59M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 222 |
| Abeona Therapeutics | 136 |
| Prelude Therapeutics | 131 |
| Orchestra BioMed Holdings | 70 |
| Cybin | 50 |
| Surrozen | 41 |
| Fennec Pharmaceuticals | 32 |
| Inhibikase Therapeutics | 16 |
OVID News
- 12 days ago - Ovid Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots - Seeking Alpha
- 2 months ago - Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) - GlobeNewsWire
- 3 months ago - Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer - GlobeNewsWire
- 4 months ago - Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Ovid Therapeutics Inc. - Special Call - Seeking Alpha
- 5 months ago - Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds - GlobeNewsWire
- 5 months ago - Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile - GlobeNewsWire